Patents by Inventor Ronald G. Almquist

Ronald G. Almquist has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell adhesion inhibitors
    Patent number: 6875743
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 5, 2005
    Assignee: Biogen, Inc.
    Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
  • Cell adhesion inhibitors
    Patent number: 6596687
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: January 13, 2000
    Date of Patent: July 22, 2003
    Assignee: Biogen, Inc.
    Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
  • Cell adhesion inhibitors
    Patent number: 6248713
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: July 11, 1995
    Date of Patent: June 19, 2001
    Assignee: Biogen, Inc.
    Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
  • Cell adhesion inhibitors
    Patent number: 6239108
    Abstract: The present invention relates to novel compounds that are useful for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention also relates to pharmaceutical formulations comprising these compounds and methods of using them for inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. The compounds and pharmaceutical compositions of this invention can be used as therapeutic or prophylactic agents. They are particularly well-suited for treatment of many inflammatory and autoimmune diseases.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: May 29, 2001
    Assignee: Biogen, Inc.
    Inventors: Ko-Chung Lin, Steven P. Adams, Alfredo C. Castro, Craig N. Zimmerman, Julio Hernan Cuervo, Wen-Cherng Lee, Charles E. Hammond, Mary Beth Carter, Ronald G. Almquist
  • Hydroxyazido derivatives and related compounds as renin inhibitors
    Patent number: 5268361
    Abstract: Novel compounds useful as renin inhibitors are provided. The compounds are hydroxyazido derivatives having the structural formula ##STR1## wherein the substituents R.sub.1 through R.sub.7 are as defined herein. Analogs of these compounds which are ketozaido derivatives are also provided. Additionally disclosed re methods for using the novel compounds to treat hypertension, and pharmaceutical compositions containing the compounds. Of particular interest are formulations for oral administration.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: December 7, 1993
    Assignee: SRI International
    Inventors: Ronald G. Almquist, Atsuro Nakazato
  • Isolated atrial peptide-degrading enzyme and novel compounds useful as inhibitors thereof
    Patent number: 5262521
    Abstract: A novel atrial peptide-degrading enzyme (ADE) is provided in isolated, purified form. The enzyme has a molecular weight of approximately 160,000 Daltons as measured by gel filtration chromatography, and is effective to cleave atrial peptides such as APII, APIII and ANF. Also provided are novel compounds useful as inhibitors of the enzyme and thus useful as blood pressure lowering agents, pharmaceutical compositions containing the inhibitors, and methods of using the inhibitors.
    Type: Grant
    Filed: June 7, 1991
    Date of Patent: November 16, 1993
    Assignee: SRI International
    Inventors: Ronald G. Almquist, Lawrence Toll
  • Orally active LHRH analogs
    Patent number: 4705778
    Abstract: Incorporation of a ketomethylene or a hydroxyethylene group in place of the amide linking group between the Pro.sup.9 and Gly.sup.10 residues of LHRH and its analogs improves the oral activity of LHRH or its analogs.
    Type: Grant
    Filed: October 22, 1985
    Date of Patent: November 10, 1987
    Assignee: SRI International
    Inventors: Ronald G. Almquist, Cris M. Olsen
  • Oxoalkanoic acid derivatives as inhibitors of angiotensin converting enzyme
    Patent number: 4329473
    Abstract: This invention relates to novel analogs of proline terminal tripeptides and related compounds and is typified by ##STR1## The compounds are potent inhibitors of angiotensin converting enzyme and as such are useful as antihypertensive agents.
    Type: Grant
    Filed: December 24, 1980
    Date of Patent: May 11, 1982
    Inventors: Ronald G. Almquist, Joseph I. De Graw